CN102883721A - 用于预防或治疗非酒精性脂肪性肝病的药物组合物以及使用所述药物组合物预防或治疗非酒精性脂肪性肝病的方法 - Google Patents
用于预防或治疗非酒精性脂肪性肝病的药物组合物以及使用所述药物组合物预防或治疗非酒精性脂肪性肝病的方法 Download PDFInfo
- Publication number
- CN102883721A CN102883721A CN2011800153529A CN201180015352A CN102883721A CN 102883721 A CN102883721 A CN 102883721A CN 2011800153529 A CN2011800153529 A CN 2011800153529A CN 201180015352 A CN201180015352 A CN 201180015352A CN 102883721 A CN102883721 A CN 102883721A
- Authority
- CN
- China
- Prior art keywords
- chemical compound
- fatty liver
- active component
- liver
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 28
- 230000002265 prevention Effects 0.000 title claims abstract description 28
- 238000011282 treatment Methods 0.000 title claims abstract description 28
- 238000000034 method Methods 0.000 title claims abstract description 24
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 title abstract description 18
- 229940125904 compound 1 Drugs 0.000 claims abstract description 75
- MFFMDFFZMYYVKS-SECBINFHSA-N sitagliptin Chemical compound C([C@H](CC(=O)N1CC=2N(C(=NN=2)C(F)(F)F)CC1)N)C1=CC(F)=C(F)C=C1F MFFMDFFZMYYVKS-SECBINFHSA-N 0.000 claims abstract description 53
- 229960004034 sitagliptin Drugs 0.000 claims abstract description 52
- 150000003839 salts Chemical class 0.000 claims abstract description 40
- SYOKIDBDQMKNDQ-XWTIBIIYSA-N vildagliptin Chemical compound C1C(O)(C2)CC(C3)CC1CC32NCC(=O)N1CCC[C@H]1C#N SYOKIDBDQMKNDQ-XWTIBIIYSA-N 0.000 claims abstract description 32
- 229960001254 vildagliptin Drugs 0.000 claims abstract description 32
- LTXREWYXXSTFRX-QGZVFWFLSA-N Linagliptin Chemical compound N=1C=2N(C)C(=O)N(CC=3N=C4C=CC=CC4=C(C)N=3)C(=O)C=2N(CC#CC)C=1N1CCC[C@@H](N)C1 LTXREWYXXSTFRX-QGZVFWFLSA-N 0.000 claims abstract description 15
- 229960002397 linagliptin Drugs 0.000 claims abstract description 15
- 241000124008 Mammalia Species 0.000 claims abstract description 3
- 150000001875 compounds Chemical class 0.000 claims description 85
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 82
- 231100000240 steatosis hepatitis Toxicity 0.000 claims description 61
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 56
- 229940095064 tartrate Drugs 0.000 claims description 54
- 208000010706 fatty liver disease Diseases 0.000 claims description 46
- 208000004930 Fatty Liver Diseases 0.000 claims description 45
- 206010019708 Hepatic steatosis Diseases 0.000 claims description 45
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 41
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 29
- 208000006454 hepatitis Diseases 0.000 claims description 19
- 239000000203 mixture Substances 0.000 claims description 19
- 238000002360 preparation method Methods 0.000 claims description 18
- 206010019668 Hepatic fibrosis Diseases 0.000 claims description 16
- 230000007863 steatosis Effects 0.000 claims description 16
- 208000008589 Obesity Diseases 0.000 claims description 13
- 235000020824 obesity Nutrition 0.000 claims description 13
- 206010012601 diabetes mellitus Diseases 0.000 claims description 11
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 10
- 201000005577 familial hyperlipidemia Diseases 0.000 claims description 7
- 230000001476 alcoholic effect Effects 0.000 claims description 6
- 150000003892 tartrate salts Chemical class 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 abstract description 3
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 210000004185 liver Anatomy 0.000 description 45
- 235000019197 fats Nutrition 0.000 description 40
- 235000011007 phosphoric acid Nutrition 0.000 description 38
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 37
- 230000000694 effects Effects 0.000 description 30
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 27
- 108010082126 Alanine transaminase Proteins 0.000 description 27
- 239000003814 drug Substances 0.000 description 27
- 235000009200 high fat diet Nutrition 0.000 description 26
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 22
- 230000014509 gene expression Effects 0.000 description 21
- 230000009467 reduction Effects 0.000 description 19
- 210000004027 cell Anatomy 0.000 description 15
- 210000001519 tissue Anatomy 0.000 description 15
- 241000699670 Mus sp. Species 0.000 description 14
- 230000002401 inhibitory effect Effects 0.000 description 14
- 231100000283 hepatitis Toxicity 0.000 description 13
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 12
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 12
- 102000004877 Insulin Human genes 0.000 description 11
- 108090001061 Insulin Proteins 0.000 description 11
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- 230000001939 inductive effect Effects 0.000 description 11
- 229940125396 insulin Drugs 0.000 description 11
- -1 iron ion Chemical class 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 239000001963 growth medium Substances 0.000 description 10
- 210000002966 serum Anatomy 0.000 description 10
- 206010061218 Inflammation Diseases 0.000 description 9
- 241000700159 Rattus Species 0.000 description 9
- 239000002253 acid Substances 0.000 description 9
- 230000037396 body weight Effects 0.000 description 9
- 230000004054 inflammatory process Effects 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- 230000004913 activation Effects 0.000 description 8
- 235000014113 dietary fatty acids Nutrition 0.000 description 8
- 239000000194 fatty acid Substances 0.000 description 8
- 229930195729 fatty acid Natural products 0.000 description 8
- 150000004665 fatty acids Chemical class 0.000 description 8
- 210000004024 hepatic stellate cell Anatomy 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 235000005911 diet Nutrition 0.000 description 7
- 230000037213 diet Effects 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 230000003203 everyday effect Effects 0.000 description 7
- 210000003494 hepatocyte Anatomy 0.000 description 7
- 239000008363 phosphate buffer Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 6
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 238000010171 animal model Methods 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000002440 hepatic effect Effects 0.000 description 5
- 231100000753 hepatic injury Toxicity 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 230000003449 preventive effect Effects 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 230000006641 stabilisation Effects 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 102000007469 Actins Human genes 0.000 description 4
- 108010085238 Actins Proteins 0.000 description 4
- 238000011740 C57BL/6 mouse Methods 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 206010016654 Fibrosis Diseases 0.000 description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 4
- 239000012981 Hank's balanced salt solution Substances 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 210000001789 adipocyte Anatomy 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 229940125782 compound 2 Drugs 0.000 description 4
- 230000004761 fibrosis Effects 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 4
- 229960003105 metformin Drugs 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 230000001603 reducing effect Effects 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 3
- 101800000224 Glucagon-like peptide 1 Proteins 0.000 description 3
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 3
- 102100031545 Microsomal triglyceride transfer protein large subunit Human genes 0.000 description 3
- 102100040918 Pro-glucagon Human genes 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 229940125753 fibrate Drugs 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 108010038232 microsomal triglyceride transfer protein Proteins 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 229920002113 octoxynol Polymers 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 3
- 239000012224 working solution Substances 0.000 description 3
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 102000018616 Apolipoproteins B Human genes 0.000 description 2
- 108010027006 Apolipoproteins B Proteins 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 102000012422 Collagen Type I Human genes 0.000 description 2
- 108010022452 Collagen Type I Proteins 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- 239000004606 Fillers/Extenders Substances 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- PLXBWHJQWKZRKG-UHFFFAOYSA-N Resazurin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3[N+]([O-])=C21 PLXBWHJQWKZRKG-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 229940123464 Thiazolidinedione Drugs 0.000 description 2
- 102000009618 Transforming Growth Factors Human genes 0.000 description 2
- 108010009583 Transforming Growth Factors Proteins 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 238000010306 acid treatment Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 230000002300 anti-fibrosis Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 229940126214 compound 3 Drugs 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 238000011496 digital image analysis Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 229960002297 fenofibrate Drugs 0.000 description 2
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 description 2
- 235000021588 free fatty acids Nutrition 0.000 description 2
- 239000001530 fumaric acid Substances 0.000 description 2
- 235000011087 fumaric acid Nutrition 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 238000010231 histologic analysis Methods 0.000 description 2
- 229960000443 hydrochloric acid Drugs 0.000 description 2
- 208000006575 hypertriglyceridemia Diseases 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 239000011976 maleic acid Substances 0.000 description 2
- 229940098895 maleic acid Drugs 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- VOFUROIFQGPCGE-UHFFFAOYSA-N nile red Chemical compound C1=CC=C2C3=NC4=CC=C(N(CC)CC)C=C4OC3=CC(=O)C2=C1 VOFUROIFQGPCGE-UHFFFAOYSA-N 0.000 description 2
- 238000011623 obesity animal model Methods 0.000 description 2
- 208000001797 obstructive sleep apnea Diseases 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000001117 sulphuric acid Substances 0.000 description 2
- 235000011149 sulphuric acid Nutrition 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 2
- 150000001467 thiazolidinediones Chemical class 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- JCZPMGDSEAFWDY-SQOUGZDYSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanamide Chemical compound NC(=O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO JCZPMGDSEAFWDY-SQOUGZDYSA-N 0.000 description 1
- FEOHYDSNGHIXOM-WLDMJGECSA-N (3R,4R,5S,6R)-3-amino-6-(hydroxymethyl)-2-methyloxane-2,4,5-triol Chemical compound CC1(O)[C@H](N)[C@@H](O)[C@H](O)[C@H](O1)CO FEOHYDSNGHIXOM-WLDMJGECSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- HVCNXQOWACZAFN-UHFFFAOYSA-N 4-ethylmorpholine Chemical compound CCN1CCOCC1 HVCNXQOWACZAFN-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 102000011690 Adiponectin Human genes 0.000 description 1
- 108010076365 Adiponectin Proteins 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 101710095342 Apolipoprotein B Proteins 0.000 description 1
- 102100040202 Apolipoprotein B-100 Human genes 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- DHHFDKNIEVKVKS-FMOSSLLZSA-N Betanin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=C1)O)=CC(C[C@H]2C([O-])=O)=C1[N+]2=C\C=C\1C=C(C(O)=O)N[C@H](C(O)=O)C/1 DHHFDKNIEVKVKS-FMOSSLLZSA-N 0.000 description 1
- DHHFDKNIEVKVKS-MVUYWVKGSA-N Betanin Natural products O=C(O)[C@@H]1NC(C(=O)O)=C/C(=C\C=[N+]/2\[C@@H](C(=O)[O-])Cc3c\2cc(O)c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)c3)/C1 DHHFDKNIEVKVKS-MVUYWVKGSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 208000034599 Dysbetalipoproteinemia Diseases 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 102000008857 Ferritin Human genes 0.000 description 1
- 108050000784 Ferritin Proteins 0.000 description 1
- 238000008416 Ferritin Methods 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 1
- 201000010252 Hyperlipoproteinemia Type III Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102000016267 Leptin Human genes 0.000 description 1
- 108010092277 Leptin Proteins 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 206010049287 Lipodystrophy acquired Diseases 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 241000238383 Loligo Species 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000713869 Moloney murine leukemia virus Species 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 108010016731 PPAR gamma Proteins 0.000 description 1
- 102100038831 Peroxisome proliferator-activated receptor alpha Human genes 0.000 description 1
- 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 1
- 229940080774 Peroxisome proliferator-activated receptor gamma agonist Drugs 0.000 description 1
- 206010036049 Polycystic ovaries Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 229940123934 Reductase inhibitor Drugs 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 201000007981 Reye syndrome Diseases 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 108010074436 Sterol Regulatory Element Binding Protein 1 Proteins 0.000 description 1
- 102100026839 Sterol regulatory element-binding protein 1 Human genes 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 206010060751 Type III hyperlipidaemia Diseases 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 208000026589 Wolman disease Diseases 0.000 description 1
- 208000035222 X-linked skeletal dysplasia-intellectual disability syndrome Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 208000005652 acute fatty liver of pregnancy Diseases 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- IYIKLHRQXLHMJQ-UHFFFAOYSA-N amiodarone Chemical compound CCCCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(I)=C(OCCN(CC)CC)C(I)=C1 IYIKLHRQXLHMJQ-UHFFFAOYSA-N 0.000 description 1
- 229960005260 amiodarone Drugs 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003579 anti-obesity Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940127088 antihypertensive drug Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000001654 beetroot red Substances 0.000 description 1
- 235000012677 beetroot red Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 235000002185 betanin Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 230000008822 capillary blood flow Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 229960001214 clofibrate Drugs 0.000 description 1
- KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 229960002656 didanosine Drugs 0.000 description 1
- FFYPMLJYZAEMQB-UHFFFAOYSA-N diethyl pyrocarbonate Chemical compound CCOC(=O)OC(=O)OCC FFYPMLJYZAEMQB-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 1
- 229960004166 diltiazem Drugs 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 210000003999 epithelial cell of bile duct Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical compound CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 230000009795 fibrotic process Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 150000002337 glycosamines Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 206010019692 hepatic necrosis Diseases 0.000 description 1
- 230000007866 hepatic necrosis Effects 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical compound C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 1
- 201000008980 hyperinsulinism Diseases 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229940045996 isethionic acid Drugs 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 229940090473 januvia Drugs 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229960000448 lactic acid Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
- 229940039781 leptin Drugs 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 208000006132 lipodystrophy Diseases 0.000 description 1
- 230000004132 lipogenesis Effects 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 238000012317 liver biopsy Methods 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000007056 liver toxicity Effects 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229940099690 malic acid Drugs 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 1
- 229960001243 orlistat Drugs 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- CYXKNKQEMFBLER-UHFFFAOYSA-N perhexiline Chemical compound C1CCCNC1CC(C1CCCCC1)C1CCCCC1 CYXKNKQEMFBLER-UHFFFAOYSA-N 0.000 description 1
- 229960000989 perhexiline Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000002824 peroxisome Anatomy 0.000 description 1
- 108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 description 1
- 229960004838 phosphoric acid Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229960005095 pioglitazone Drugs 0.000 description 1
- IWELDVXSEVIIGI-UHFFFAOYSA-N piperazin-2-one Chemical class O=C1CNCCN1 IWELDVXSEVIIGI-UHFFFAOYSA-N 0.000 description 1
- 150000003053 piperidines Chemical class 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 229920001992 poloxamer 407 Polymers 0.000 description 1
- 201000010065 polycystic ovary syndrome Diseases 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 210000003240 portal vein Anatomy 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- HSSLDCABUXLXKM-UHFFFAOYSA-N resorufin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3N=C21 HSSLDCABUXLXKM-UHFFFAOYSA-N 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 235000021003 saturated fats Nutrition 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 231100000489 sensitizer Toxicity 0.000 description 1
- 208000025869 skeletal dysplasia-intellectual disability syndrome Diseases 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000003760 tallow Substances 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 229960004559 theobromine Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 1
- 229960002555 zidovudine Drugs 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本发明提供用于预防和治疗非酒精性脂肪性肝病(NAFLD)的药物组合物,其包含选自式1表示的化合物1、西格列汀、维格列汀、利拉利汀或它们的药学可接受的盐的活性成分。另外,本发明提供用于预防或治疗非酒精性脂肪性肝病的方法,其包括向有此需要的包括人在内的哺乳动物给药有效量的选自式1表示的化合物1、西格列汀、维格列汀、利拉利汀或它们的药学可接受的盐的活性成分。另外,本发明提供式1表示的化合物1、西格列汀、维格列汀、利拉利汀或它们的药学可接受的盐用于制备预防或治疗非酒精性脂肪性肝病的药物组合物的用途。
Description
技术领域
本发明涉及用于预防或治疗非酒精性脂肪性肝病的药物组合物以及用于预防或治疗脂肪性肝病的方法。
背景技术
非酒精性脂肪性肝病(NAFLD)指一系列广泛的疾病,包括无过度饮酒的患者中的不伴有炎症反应的单纯脂肪变性(simple steatosis),以及由单纯脂肪变性的进展引起并表现出肝细胞炎症的非酒精性脂肪性肝炎(NASH)、肝纤维化和肝硬化,并且与前一术语非酒精性脂肪性肝炎相比非酒精性脂肪性肝病的概念更宽泛(Ludwig J等人,Mayo Clin Proc 1980,55(7):434-438)。
根据病理学原因可将NAFLD分为原发性NAFLD和继发性NAFLD。已知原发性NAFLD是由代谢综合征特有的高脂血症、糖尿病、肥胖症等引起的,而继发性NAFLD是由营养方面的原因(体重骤减、饥饿、肠旁路术)、各种药物(糖皮质激素、雌激素、他莫昔芬、甲氨蝶呤、齐多夫定、胺碘酮、四环素、去羟肌苷、可卡因、地尔硫卓、哌克昔林)、毒性物质(毒蘑菇、细菌毒素)、代谢方面的原因(脂肪营养不良、血β脂蛋白异常、Weber-Christian综合征、沃尔曼氏病、妊娠急性脂肪肝、瑞氏综合征)和其他因素(炎症性肠综合征、AIDS感染;HIV感染)引起的(Adams LA等人,CMAJ 2005,172(7):899-905)。已知与糖尿病和肥胖症(它们是作为主要因素的代谢综合征的重要特征)相关的NAFLD的发病率为约50%糖尿病患者,约76%肥胖症患者和绝大多数肥胖的糖尿病患者(Gupte P等人,JGastroenterol Hepatol 2004,19(8):854-858)。另外,当对丙氨酸转氨酶(ALT)水平升高的糖尿病患者和肥胖症患者进行肝活组织检查时,脂肪性肝炎的发病率为18-36%(Braillon A等人,Gut 1985,26(2):133-139),并且已知脂肪性肝炎是由胰岛素抵抗引起的。另外,在还患有糖尿病、肥胖症和高脂血症的脂肪性肝炎患者中,脂肪性肝炎进展成肝硬化的比例随疾病的研究阶段而不同。据报道,在3-11年的研究阶段中从脂肪性肝炎进展成肝硬化的患者的比例为4-26%,并且此类患者的死亡率比一般人群组高(Powell EE等人,Hepatology 1990,11(1):74-80,Bacon BR等人,Gastroenterology 1994,107(4):1103-1109,Matteoni CA等人,Gastroenterology 1999,116(6):1413-1419)。
已知由于全身因素例如局部因素的变化和胰岛素抵抗引起的脂质肝内流/合成和释放/氧化之间的失衡导致可能出现与NAFLD直接相关的肝脏甘油三酯蓄积和随之发生的肝细胞损伤。即,已知由胰岛素抵抗引起的高胰岛素血症导致脂肪酸肝内流的水平高于肝细胞线粒体氧化脂肪酸的能力,从而引起甘油三酯的肝内蓄积(Reid AE.Gastroenterology 2001,121(3):710-723)。另外,胰岛素抵抗导致脂肪生成性转录因子过氧化物酶体增殖物激活受体-γ(PPAR-γ)和甾醇调节因子结合蛋白-1c(SREBP-1c)的表达增加(上调),这可导致由肝脂肪重新生成增加引起的甘油三酯的蓄积(Fromenty B等人,Diabetes Metab 2004,30(2):121-138)。
脂肪以极低密度脂蛋白(VLDL)的形式从肝脏释放进入血液。同时,VLDL是由将甘油三酯与载脂蛋白B(apo B)结合的微粒体甘油三酯转移蛋白(MTP)形成的。胰岛素抵抗导致脂肪组织中脂肪的分解增加,由此导致血脂肪酸增加。随后MTP活性和apo B合成降低导致肝脏的脂肪释放减少和甘油三酯蓄积(Namikawa C等人,J Hepatol 2004,40(5):781-786)。胰岛素抵抗对于NAFLD的发病特别重要的原因是因为以糖尿病、肥胖症和高脂血症为特征的代谢综合征与非酒精性脂肪性肝病之间具有高度相关性。脂肪蓄积的肝脏易受到继发性损伤并因此进展成肝细胞炎症和纤维化。
此类继发性损伤是由包括肿瘤坏死因子-α(TNF-α)、瘦素和脂连素(adiponectin)在内的各种脂肪细胞因子、氧化应激、脂质过氧化、脂肪酸增加(Hui JM等人,Hepatology 2004,40(1):46-54)以及接受空肠回肠旁路术的患者中来自肠道的细菌内毒素(Day CP和James OF.Gastroenterology1998,114(4):842-845)引起的。
由于肝损伤和窦状隙周围细胞纤维化的进展,具有脂滴沉积的肝细胞抑制了微血管血流,这进而导致氧和营养物质的交换减少并出现微血管炎症反应(Magalotti D等人,Dig Liver Dis 2004,36(6):406-411)。另外,脂肪性肝炎患者表现出血中铁蛋白和铁离子的水平升高,并且铁离子、肿瘤生长因子-β1(TGF-β1)和细胞因子的水平升高导致肝星状细胞的活化和胶原合成,由此导致肝纤维化和肝硬化的进展(Pietrangelo A等人,Hepatology 1994,19(3):714-721)。
同时,最近已报道NAFLD与包括动脉粥样硬化在内的心血管疾病(CVD)、脑血管疾病(Francazani A等人,Am J Med 2008,121:72-78)、微血管疾病、肾病和视网膜病(Targher G等人,Diabetologia 2008;51(3):444-450)、多囊卵巢综合征(Targher G等人,Atherosclerosis 2007,191:235-240,Cerda C等人,J Hepatol 2007,47:412-417)或阻塞性睡眠呼吸暂停(OSA)(Tanne F等人,Hepatology 2005,41:1290-1296)有关。
到目前为止,还没有确立的NAFLD治疗方法。这是因为NAFLD的发病与多种因素相关,例如糖尿病、肥胖症、冠心病以及起居习惯。肥胖症是NAFLD治疗中的重要靶标,因为体重减轻可能导致与胰岛素抵抗(其为肝损伤的风险因素)相关的因素、脂肪酸向肝脏的内流量以及炎性因子或纤维化脂肪因子减少。尽管通过控制饮食和锻炼身体来减少体重可能引起丙氨酸转氨酶(ALT)水平和肝甘油三酯含量降低,但是在患有坏死性炎症或肝纤维化的患者中几乎未见由体重减少引起的ALT水平和肝甘油三酯含量的减少(Harrison SA等人,Gut 2007,56:1760-1769)。饮食饱和脂肪的摄入与肝甘油三酯含量和胰岛素抵抗高度相关(Westerbacka J等人,J ClinEndocrinol Metab 2005,2804-2809),因此控制饮食是非常重要的。已知通过为了减少体重和降低胰岛素抵抗进行锻炼身体提供脂肪肝的组织学改善(Ueno T等人,J Hepatol 1997,27:103-110)。
据报道,奥利司他(其为肠脂肪酶抑制剂并被用作口服抗肥胖症药物)表现出对脂肪性肝炎患者的肝脏的组织学改善(Hussein O等人,Dig Dis Sci2007,52:2512-2519)。然而,还不清楚此类组织学改善是否归因于体重的减少或其他机制。
已知II型糖尿病和胰岛素抵抗与肝脏的炎症和纤维化相关(Adachi M等人,Gastroenterology 2007,132:1434-1446)。当向具有非酒精性脂肪性肝病的临床表现的II型糖尿病患者给药二甲双胍时,通过血液学检查和核磁共振成像未清楚地发现脂肪肝的改善。然而,据报道,与给药维生素E或减肥药的组相比,在无糖尿病表现的NAFLD患者中持续一年给药二甲双胍表现出血肝酶水平以及肝坏死性炎症和纤维化降低(Bugianesi E等人,Am JGastroenterol 2005,100:1082-1090)。
噻唑烷二酮(TZD)类药物是PPAR-γ激动剂,其提高胰岛素敏感性,抑制脂肪在肝脏和肌肉中的蓄积,并且增加脂肪细胞中具有抗炎和抗纤维化作用的脂肪因子的分泌。已报道TZD类药物在非酒精性脂肪性肝病的动物模型中表现出对肝脏的直接抗纤维化作用(Galli A等人,Gastroenterology2002,122:1924-1940)。
已报道第二代TZD吡格列酮在脂肪性肝炎患者中表现出改善脂肪肝并显著改善炎症反应和坏死性反应(Belfort R等人,N Engl J Med 2006,355:2297-2307),但是其缺点在于,当脂肪性肝炎患者停止服用该药物时脂肪肝和炎症会加重(Lutchman G等人,Hepatology 2007,46:424-429)。
血脂异常与非酒精性脂肪性肝病相关。20-80%的非酒精性脂肪性肝病患者中会出现高甘油三酯血症,而且贝特类药物(降低血甘油三酯的药物)可能对高甘油三酯血症具有治疗益处。贝特类药物是PPAR-α受体激动剂并且已在脂肪性肝炎的动物模型中研究了它们的治疗功效((Ip E等人,Hepatology 2004,39:1286-1296)。遗憾的是,据报道,贝特类药物之一氯贝丁酯在临床试验中对肝酶水平和组织损伤没有作用(Laurin J等人,Hepatology 1996,23:1464-1467)。
对于具有3-羟基-3-甲基戊二酰CoA还原酶抑制剂(HMG CoA还原酶抑制剂)(为降低胆固醇的物质)的机制的他汀类药物而言,尽管还未确立它们在NAFLD患者中的作用,但是这些他汀类药物的优点在于对II型糖尿病患者和具有心血管疾病风险因素的患者而言是安全的处方。然而,他汀类药物的肝毒性可能会不利地导致丙氨酸转氨酶的血液水平升高(Browning J等人,Hepatology 2006,44:466-471)。
对于抗高血压药物而言,α-阻断剂在表现出肝纤维化和脂肪性肝炎的动物模型中显示出治疗功效(Hirose A等人,Hepatology 2007,45:1375-1381)并且在临床试验中在脂肪性肝炎患者中表现出减少肝纤维化的血清因素并具有胰岛素致敏作用,由此表现出其治疗潜能(Ichikawa Y等人,Intern Med2007,46:1331-1336)。
发明内容
技术问题
因此,本发明旨在提供用于预防和治疗非酒精性脂肪性肝病(NAFLD)的药物组合物和使用所述组合物治疗NAFLD的方法。
解决技术问题的技术方案
本发明涉及用于预防或治疗非酒精性脂肪性肝病的药物组合物,其包含选自下式1、2、3或4表示的化合物或其药学可接受的盐的活性成分。
式I表示的化合物1是((R)-4-[(R)-3-氨基-4-(2,4,5-三氟苯基)丁酰基]-3-(叔丁氧基甲基)哌嗪-2-酮)并且公开于韩国专利申请No.2008-0036052。
式2表示的化合物2是西格列汀(sitagliptin)并且以商品名Januvia在市面上销售;式3表示的化合物3是维格列汀(vildagliptin)并且以商品名Galvus在市面上销售;式4表示的化合物4被称作利拉利汀(linagliptin)。
[式1]
[式2]
[式3]
[式4]
本发明的化合物1-4可通过常规已知的方法合成或者可商购得到(例如,可从中国Trademax购买维格列汀)。
如上文式1或2所示,化合物1或2可在哌嗪酮的β碳和3-位碳具有不对称中心。单一对映异构体、单一非对映异构体、外消旋物或非对映异构体的混合物可属于本发明的式1或2的化合物1或2的范围。另外,本发明的式1或2的化合物1或2可为互变异构体的形式,并且单一互变异构体及其混合物可属于本发明的化合物1或2的范围。本发明的化合物1或2的包含β氨基的杂化合物(hetero compound)包括其药学可接受的盐以及从其制备的水合物和溶剂合物。化合物1或2的包含β氨基的杂化合物的药学可接受的盐可通过本领域已知的用于制备盐的常规方法制得。另外,化合物3和4包括所有可能的旋光异构体及其药学可接受的盐。
本文使用的术语“药学可接受的盐”指从包括无机碱或有机碱和无机酸或有机酸在内的药学可接受的无毒的碱或酸制备的盐。衍生自无机碱的盐的实例包括具有铝、铵、钙、酮、铁(I)、铁(II)、锂、镁、锰、钾、钠和锌的盐。特别优选铵盐、钙盐、镁盐、钾盐或钠盐。固体盐可以一种或多种晶体结构的形式或以水合物的形式存在。衍生自药学可接受的无毒的有机碱的盐的实例包括伯胺、仲胺和叔胺、包括天然存在的取代的胺在内的取代的胺、环状胺以及碱离子交换树脂,例如精氨酸、甜菜碱、咖啡因、胆碱、N',N-二苄基乙烯二胺、二乙胺、2-二乙基氨基乙醇、2-二甲基氨基乙醇、乙醇胺、乙二胺、N-乙基吗啉、N-乙基哌啶、葡糖胺、氨基葡糖、组氨酸、海巴胺(hydrabamine)、异丙胺、赖氨酸、甲基葡糖胺、吗啉、哌嗪、哌啶、聚胺树脂、普鲁卡因、嘌呤、可可碱、三乙胺、三甲胺、三丙胺和氨丁三醇的盐。
当本发明化合物为碱性时,可从包括无机酸或有机酸在内的药学可接受的无毒的酸制备其盐。所述酸的实例包括乙酸、苯磺酸、苯甲酸、樟脑磺酸、柠檬酸、乙磺酸、富马酸、葡糖酸、谷氨酸、氢溴酸、盐酸、羟乙磺酸、乳酸、马来酸、苹果酸、扁桃酸、甲磺酸、粘酸、硝酸、扑酸、泛酸、磷酸、琥珀酸、硫酸、酒石酸以及对甲苯磺酸。优选柠檬酸、氢溴酸、盐酸、马来酸、磷酸、硫酸、富马酸或酒石酸。
本发明的化合物1、2、3或4或其药学可接受的盐的水合物可被理解为包含通过非共价分子间力结合的化学计量的或非化学计量的量的水。所述水合物可包含多于1当量的水,通常包含1-5当量的水。此类水合物可通过在水或含水溶剂中使本发明的化合物1或2或其药学可接受的盐结晶制得。
在本发明的药物组合物中,所述活性成分优选为式1表示的化合物1或其药学可接受的盐,并且所述活性成分更优选为化合物1的酒石酸盐。
在本发明的药物组合物中,所述活性成分优选为西格列汀或其药学可接受的盐,并且更优选磷酸西格列汀。
在本发明的药物组合物中,所述活性成分优选为维格列汀或其药学可接受的盐。
在本发明的药物组合物中,所述活性成分优选为利拉利汀或其药学可接受的盐。
本发明的用于预防或治疗非酒精性脂肪性肝病的药物组合物可以常规药物制剂的形式使用。即,在实际的临床给药时,可以各种口服和肠胃外剂型给药所述药物组合物。在本发明中,优选口服给药。另外,在将所述药物组合物配制成期望的剂型时,可使用本领域常规已知和使用的稀释剂或赋形剂,例如填充剂、增量剂(extender)、粘合剂、润湿剂、崩解剂或表面活性剂。用于口服给药的固体制剂可包括片剂、丸剂、散剂、颗粒剂、胶囊剂等,并且此类固体制剂是通过将活性成分与至少一种赋形剂例如淀粉、碳酸钙、蔗糖、乳糖和明胶混合制得。另外,除所述赋形剂外还可使用润滑剂例如硬脂酸镁或滑石。
用于口服给药的液体制剂包括混悬剂、用于内服的液体制剂、乳剂、糖浆剂等。除了常用的稀释剂例如水或液体石蜡,所述液体制剂还可包含各种赋形剂,例如润湿剂、甜味剂、芳香剂和防腐剂。用于肠胃外给药的制剂包括无菌水溶液剂、非水溶液剂、混悬剂、乳剂、冻干制剂和栓剂。可使用丙二醇、聚乙二醇、植物油例如橄榄油、可注射的酯例如油酸乙酯等作为非水溶液剂或混悬剂的溶剂。可使用Witepsol、macrogol、吐温61、可可脂、月桂精脂(laurin butter)、甘油明胶等作为栓剂的基质。
本发明的药物组合物的活性成份的每日剂量或剂量为0.1-1000mg/kg,但是可随患者的体重、年龄、性别、健康状况和饮食习惯、给药时间和途径、排泄速率以及疾病的严重度而变化。
在本发明,非酒精性脂肪性肝病(NAFLD)包括原发性和继发性非酒精性脂肪性肝病,并且优选指由原发性高脂血症、糖尿病或肥胖症引起的非酒精性脂肪性肝病。
另外,在本发明中,所述非酒精性脂肪性肝病(NAFLD)包括单纯脂肪变性、非酒精性脂肪性肝炎(NASH)以及由于这些疾病的进展而发生的肝纤维化和肝硬化。
除了式1、2、3或4的化合物或其药学可接受的盐,本发明的药物组合物还可包含至少一种表现出相同或相似功能的活性成分。
另外,本发明提供用于预防或治疗非酒精性脂肪性肝病的方法,其包括向有此需要的哺乳动物(包括人)给药有效量的式1、2、3或4表示的化合物或其药学可接受的盐。
本文使用的术语“给药”表示通过任何适合的方法将本发明的药物组合物引入到患者中的方法。可通过任何常规的给药途径给药本发明的药物组合物,只要所述药物组合物能够到达靶组织。可将所述组合物例如但不限于口服、腹膜内、静脉内、肌肉内、皮下、透皮、鼻内、肺内、直肠、腔内或鞘内给药。
可每日一次给药或以固定的时间间隔每日两次或多次给药本发明的药物组合物。
为了预防和治疗非酒精性脂肪性肝病,可将本发明的药物组合物单独使用或与应用手术、激素治疗、药物治疗和生物反应调节剂的方法组合使用。
另外,本发明提供式1、2、3或4的化合物或其药学可接受的盐用于制备预防和治疗非酒精性脂肪性肝病的药物组合物的用途。
本发明的有益效果
本发明的药物组合物具有预防和治疗甘油三酯蓄积(非酒精性脂肪肝的典型损伤的表现)的作用,以及使血液中检测到的肝细胞损伤指示物丙氨酸转氨酶(ALT)正常化的作用。另外,本发明的药物组合物抑制导致肝纤维化的肝星状细胞(HSC)的活化和分化,由此抑制肝纤维化并且还抑制肝纤维化向肝硬化的进展,这提供预防和治疗肝纤维化或肝硬化的作用。因此,本发明的药物组合物可用作预防和治疗非酒精性脂肪性肝病的药剂。
本发明的治疗方法可用于预防和治疗非酒精性脂肪性肝病。
附图简述
图1显示化合物1的酒石酸盐或磷酸西格列汀在患有诱导的非酒精性脂肪肝的小鼠中的降低血清丙氨酸转氨酶(ALT)的作用。
图2是肝甘油三酯含量分析图,其显示化合物1的酒石酸盐或磷酸西格列汀在患有诱导的非酒精性脂肪肝的小鼠中的降低肝甘油三酯的作用。
图3是组织样本照片,其显示化合物1的酒石酸盐在患有诱导的非酒精性脂肪肝的小鼠中的降低肝甘油三酯的作用。
图4显示化合物1的酒石酸盐在患有诱导的非酒精性脂肪肝的大鼠中的降低血清ALT的作用。
图5是肝甘油三酯含量分析图,其显示化合物1的酒石酸盐在患有诱导的非酒精性脂肪肝的大鼠中的降低肝甘油三酯的作用。
图6是组织样本照片,其显示化合物1的酒石酸盐在患有诱导的非酒精性脂肪肝的大鼠中的降低肝甘油三酯的作用。
图7的照片显示通过组织样本的图像分析得到的脂滴面积/样本单位面积,表明化合物1的酒石酸盐在患有诱导的非酒精性脂肪肝的大鼠中的降低肝甘油三酯的作用。
图8是组织样本图像,其显示化合物1的酒石酸盐、磷酸西格列汀和维格列汀对高脂肪饲料诱导的小鼠脂肪肝的预防肝甘油三酯蓄积的作用。
图9是电泳照片,其显示化合物1的酒石酸盐、磷酸西格列汀、维格列汀和利拉利汀在活化的肝星状细胞中减少目标蛋白表达的作用。
图10显示化合物1的酒石酸盐、磷酸西格列汀和维格列汀对游离脂肪酸诱导的肝细胞脂肪蓄积的抑制作用。
图11是显示化合物1的酒石酸盐、磷酸西格列汀和维格列汀对CCl4诱导的急性肝损伤动物模型中的TGF-β1mRNA表达的抑制作用的分析图。
〈参考数值和标记的描述〉
在图1、2、4、5和7中,*:与标准饲料组相比在95%置信区间内的显著增加(p<0.05),#:与高脂肪饲料组相比在95%置信区间内的显著降低(p<0.05)。
在图10中,*:与0.1%DMSO对照组相比在95%置信区间内的显著增加(p<0.05),**:与0.1%DMSO对照组相比在99%置信区间内的显著降低(p<0.01)。
发明实施方式
下文中,参考以下实施例更详细地描述本发明。然而,提供以下实施例仅用于举例说明本发明,不应认为对本发明的范围和精神具有限制性。
实施例1:化合物1的酒石酸盐和磷酸西格列汀对高脂肪饲料诱导的
小鼠单纯脂肪变性的预防作用
为了研究化合物1的酒石酸盐(根据韩国专利申请No.2008-0036052中记载的方法制备)和磷酸西格列汀对单纯脂肪变性的预防作用,进行以下实验。
使6周龄的雄性C57BL/6小鼠稳定化,然后分成5个组。一组给予含10%脂肪的标准饲料(商品名:D 12450B,由Research Diets生产),一组给予含60%脂肪的高脂肪饲料(商品名:D12492,由Research Diets生产)。剩余三组为药物治疗组,给予通过将高脂肪饲料与药物混合而特别配制的混合有药物的饲料。对于化合物1的酒石酸盐而言,为了提供100mg/kg和300mg/kg(化合物1的酒石酸盐基于每日平均高脂肪饲料消耗量的每日目标剂量),通过将高脂肪饲料分别与0.2重量%和0.5重量%化合物1的酒石酸盐混合来配制饲料。对于磷酸西格列汀而言,为了提供300mg/kg(基于每日平均高脂肪饲料消耗量的每日目标剂量),通过将高脂肪饲料与约0.5重量%磷酸西格列汀混合来配制饲料。向各药物治疗组给药如此配制的混合有药物的饲料。在提供每一种饲料8周、16周和24周后,将动物解剖并分离血清。然后使用血液分析仪测定血清ALT水平(丙氨酸转氨酶)、GPT(谷氨酸丙酮酸转氨酶)(表1和图1)。将切除的肝脏在5(v/v)%Triton-X溶液中匀浆,向其中加入甘油三酯工作液[通过将无甘油试剂(F6428,Sigma)和甘油三酯试剂(F2449,Sigma)以4:1(v/v)的比例混合制得],然后测定540nm处的吸光度以测定甘油三酯的含量(表1和图2)。另外,为了观察组织学脂肪分布,将一部分切除的肝脏固定在10(v/v)%福尔马林溶液中,然后制备组织样本,之后进行苏木精&曙红染色并使用图像分析程序(计算机图像分析)拍照(图3,染成紫色的部分表示正常的肝组织,染成白色的部分表示脂滴)。
结果如图1所示,化合物1的酒石酸盐和磷酸西格列汀的提供在第16周和第24周显示出血清丙氨酸转氨酶(ALT)的显著降低。另外,在肝甘油三酯分析(图2)和组织学分析(图3)中,与高脂肪饲料饲养组相比,肝甘油三酯含量也表现出显著降低。这些结果表明,化合物1的酒石酸盐和磷酸西格列汀降低高脂肪饲料诱导的脂肪肝的肝甘油三酯含量并因此对脂肪肝具有预防功效。
[表1]化合物1的酒石酸盐和磷酸西格列汀对高脂肪饲料诱导的小鼠单纯脂肪变性的脂肪肝预防作用
*表示与标准饲料饲养组相比显著增加(P<0.05)
#表示与高脂肪饲料饲养组相比显著降低(P<0.05)
实施例2:化合物1的酒石酸盐对高脂肪饲料诱导的大鼠单纯脂肪变
性的治疗作用
为了研究化合物1的酒石酸盐(根据韩国专利申请No.2008-0036052中记载的方法制备)对单纯脂肪变性的作用,进行以下实验。
使6周龄的雄性大鼠(Wistar大鼠)稳定化,然后分成2个组。在24周内分别给予动物组含10%脂肪的标准饲料(商品名:D 12450B,由Research Diets生产)和含60%脂肪的高脂肪饲料(商品名:D12492,由Research Diets生产)。当在提供饲料的第22周计算饲料消耗量时,高脂肪饲料饲养组表现出33.40g/kg的饲料摄入。为了提供化合物1的酒石酸盐的每日目标剂量10mg/kg,通过将高脂肪饲料与0.03重量%化合物1的酒石酸盐混合来配制饲料。提供每一种饲料24周后,将动物分成高脂肪饲料饲养组(n=8)、用高脂肪饲料+0.03重量%化合物1的酒石酸盐饲养的组(n=8)和标准饲料饲养组(n=8),然后另饲养14周。然后将动物解剖并分离血清。然后使用血液分析仪测定血清ALT水平(丙氨酸转氨酶)、GPT(谷氨酸丙酮酸转氨酶)(图4)。将切除的肝脏在5(v/v)%Triton-X溶液中匀浆,向其中加入甘油三酯工作液[通过将无甘油试剂(F6428,Sigma)和甘油三酯试剂(F2449,Sigma)以4:1(v/v)的比例混合制得],然后测定540nm处的吸光度以测定甘油三酯的含量(图5)。另外,为了观察组织学脂肪分布,将一部分切除的肝脏固定于10(v/v)%福尔马林溶液中,然后制备组织样本,之后进行苏木精&曙红(HE)染色并使用图像分析程序(计算机图像分析)拍照(图6,染成紫色的部分表示正常的肝组织,白色部分表示脂滴)。然后计算脂滴面积/样本单位面积(图7)。
结果如图4所示,化合物1的酒石酸盐的给药表现出血清丙氨酸转氨酶(ALT)的显著降低。另外,在肝甘油三酯分析(图5)和组织学分析(图7)中,与高脂肪饲料饲养组相比肝甘油三酯含量也表现出显著降低。这些结果表明,化合物1的酒石酸盐降低既有脂肪肝的肝甘油三酯含量并因此可用作治疗脂肪肝的药剂。
实施例3:化合物1的酒石酸盐、磷酸西格列汀和维格列汀对高脂肪
饲料诱导的小鼠单纯脂肪变性的预防非酒精性脂肪肝的作用
为了研究化合物1的酒石酸盐对非酒精性脂肪肝(单纯脂肪变性)的预防作用,进行以下实验。
使7周龄的雄性C57BL/6小鼠稳定化,然后根据体重和血糖水平分成9个组(n=9)。以10ml/kg的剂量向标准饲料饲养组和高脂肪饲料饲养组每日一次口服给药每一种饲料的媒介物溶液(0.5%MC(甲基纤维素)),并对应所命名的组,向剩余的组每日一次口服给药分别与30、100和300mg/kg剂量的化合物1的酒石酸盐、100和300mg/kg剂量的磷酸西格列汀以及100mg/kg和300mg/kg剂量的维格列汀混合的高脂肪饲料,持续28天。末次口服给药后24小时,将动物解剖并将切除的肝脏在5(v/v)%Triton-X溶液中匀浆,向其中加入甘油三酯工作液,然后测定540nm处的吸光度以测定甘油三酯的含量(表2)。另外,将一部分切除的肝脏固定于10(v/v)%福尔马林溶液中,然后制备组织样本,之后进行苏木精&曙红(HE)染色并拍照(图8)。
[表2]化合物1的酒石酸盐、磷酸西格列汀和维格列汀对高脂肪饲料诱导的小鼠单纯脂肪变性的预防非酒精性脂肪肝的作用
*通过将高脂肪饲料相对于标准饲料的增加幅度(increase width)作为100%而得到的产生增加的抑制%
如表2所示,当与标准饲料饲养组相比时,高脂肪饲料饲养组表现出肝甘油三酯含量增加54%;以300mg/kg的剂量给药化合物1的酒石酸盐的组表现出肝甘油三酯含量增加11%;以100mg/kg的剂量给药磷酸西格列汀的组表现出肝甘油三酯含量增加21%;以300mg/kg的剂量给药维格列汀的组表现出肝甘油三酯含量增加11%,因此表明本发明的化合物对高脂肪饲料诱导的脂肪肝的发生具有预防作用。
另外,相对于高脂肪饲料饲养组,肝甘油三酯含量的最大减量在给药化合物1的酒石酸盐的组中最大值为81%,在给药磷酸西格列汀的组中最大值为61%,在给药维格列汀的组中最大值为79%,因而也表明本发明的化合物表现出对脂肪肝的发生的预防功效。当对组织样本拍照用于该预防功效的组织学评价时,验证了化合物1的酒石酸盐、磷酸西格列汀和维格列汀使脂滴减少(图8)。这些结果表明,所有这三种药物对脂肪肝的发生具有预防功效。
实施例4:化合物1的酒石酸盐、磷酸西格列汀、维格列汀和利拉利
汀对大鼠肝星状细胞活化的抑制作用
根据以下细胞培养法试验了本发明的化合物对肝星状细胞活化的抑制作用。将体重为500-700g的雄性大鼠(Wistar大鼠)麻醉,然后将腹部切开,使导管与肝门静脉连接,然后连续灌注含有肝素的汉克平衡盐溶液(HBSS)和含有I型胶原酶的HBSS。灌注完成后,切除肝脏,用手术剪磨碎,加入含有I型胶原酶的HBSS,然后于37℃振摇培养15分钟。
使完全磨碎的液态肝组织通过纱布并以500g离心10分钟。将所得混合的细胞沉淀用磷酸盐缓冲液洗涤,然后以100g离心5分钟,并收集上清。进一步将上清以500g离心10分钟以获得沉淀,向其中加入Ficoll液(GEHealthcare)和Percoll液(GE Healthcare)的9:1(v/v)混合物,然后混合。将磷酸盐缓冲液轻轻地放置于混合层上,之后以1400g离心15分钟。然后回收上层和下层之间形成的细胞层并用含有10(v/v)%胎牛血清的Dulbecco改良的Eagle培养基(DMEM)洗涤一遍。以3.1×105个细胞/cm2的密度加入所得细胞,24小时后将培养基用新鲜的培养基替换,培养7天,其中每隔2-3天替换培养基。然后,在包含1ng/ml人转化生长因子(TGF)β1的培养基和不含TGFβ1的培养基中,以规定的浓度下处理药物。将TGFβ1溶解于二甲亚砜(DMSO)中,达到为所述药物的期望的处理浓度的1000倍的浓度,在培养基中稀释1000倍得到1-倍(X)体积,然后处理细胞。
用药物处理7天后,收获培养基并用磷酸盐缓冲液洗涤。向其中加入包含表面活性剂的缓冲液将细胞裂解。然后将蛋白质定量,在4-12%Bis-Tris凝胶(Invitrogen)上进行电泳并转移到硝酸纤维素膜上。使转移的蛋白与α-平滑肌肌动蛋白(α-SMA)或TGFβ1的特异性一抗反应,然后与马辣根过氧化物酶共轭的特异性二抗反应。使用化学发光液验证目标蛋白的表达水平并根据肌动蛋白(β-肌动蛋白)表达水平进行校正(图9)。基于TGFβ1-处理的阳性对照组相对于仅加入了DMSO的阴性对照组的蛋白质表达的增量,将100μM各本发明的化合物引起的所观察到的蛋白质表达的减量表示为药物诱导减量百分比(表3)。
[表3]对活化的肝星状细胞中的活性指示物蛋白的表达降低作用
结果如表3和图9所示,验证了化合物1的酒石酸盐、磷酸西格列汀、维格列汀和利拉利汀降低了TGFβ1和α-SMA(它们是肝纤维化的病理生理学的重要因素,其由于大鼠活化的肝星状细胞中的h TGFβ1而增加)的蛋白表达水平,并且还验证了使用较高浓度的化合物1的酒石酸盐时TGFβ1和α-SMA的蛋白表达减量增加(图9)。这些结果表明,化合物1的酒石酸盐、磷酸西格列汀、维格列汀和利拉利汀能够表现出对脂肪性肝炎或肝纤维化的疗效。
实施例5:化合物1的酒石酸盐和磷酸西格列汀对游离脂肪酸诱导的
人类肝癌细胞的细胞内脂肪蓄积的抑制作用
用游离的脂肪酸处理肝细胞导致细胞内脂肪蓄积增加。通过用游离脂肪酸和药物进行组合处理,使用甘油三酯染色法定量单一药物对细胞内脂肪蓄积的抑制作用。
将人肝癌细胞系HepG2细胞在包含10(v/v)%胎牛血清的最低必需培养基(MEM)中培养48小时。然后用0.5mM游离脂肪酸混合物(通过将油酸酯和棕榈酸酯(Sigma)以2:1的摩尔比溶解于包含1(v/v)%胎牛血清的MEM中制得)替换培养基,向其中加入0.1(v/v)%二甲亚砜(DMSO)或各受试药物,然后将细胞培养24小时。对于阴性对照组,用0.1(v/v)%二甲亚砜处理包含1(v/v)%胎牛血清的MEM,但不加入游离脂肪酸。培养完成后,除去培养基并用磷酸盐缓冲液洗涤细胞。将溶解于包含1(v/v)%PluronicF127(Invitrogen)的二甲亚砜中的10mM尼罗红(Sigma)未稀释溶液1000倍稀释于磷酸盐缓冲液中并加入细胞中,然后在避光条件下于37℃、200rpm将细胞内脂肪染色30分钟。染色完成后,弃去上清并用磷酸盐缓冲液替换,然后在488nm激发光波长和550nm发射光波长的条件下测定荧光强度。然后,为了根据细胞计数校正偏差,向同一孔中加入包含溶解于其中的10μM刃天青(Sigma)的磷酸缓冲液。之后,在避光条件下于37℃反应1小时之前和之后,使用荧光计在535nm激发光波长和580nm发射光波长的条件下测定荧光强度,由此测定由细胞内线粒体活性还原并形成的试卤灵引起的荧光强度的增加。使用尼罗红荧光强度的数值(根据刃天青还原引起的荧光强度的增加进行了校正),将实验结果表示为用游离脂肪酸处理引起的相对于阴性对照组的脂肪蓄积增加的百分比。
结果如图10所示,化合物1的酒石酸盐和磷酸西格列汀表现出对游离脂肪酸诱导的肝细胞内脂肪蓄积的剂量依赖性抑制。其在1μM的剂量下表现出的28.7±3.2%抑制作用等于GLP-1(已知GLP-1通过活化肝细胞膜的胰高血糖素样肽-1(GLP-1)受体抑制脂肪酸生物合成)在100nM的剂量下表现出的28.0±4.9%抑制作用(Ding X,等人,Hepatology 2006,43:173-181;Gupta NA,等人,Hepatology 2010,5l(5):1584-1592),还等于非诺贝特(已知非诺贝特通过促进脂肪酸氧化减少脂肪蓄积)在30μM的剂量下表现出的35.6±6.5%抑制作用(Hahn SE & Goldgerg DM,BiochemPharmacol 1992,43(3):625-33),还等于二甲双胍(据报道二甲双胍通过活化AMPK激活性蛋白激酶(AMPK)促进脂肪酸氧化并抑制脂肪酸生物合成)在1mM的剂量下表现出的23.6±5.0%抑制作用(Zang M等人,J Biol Chem,2004,279(46):47898-47905)。这些结果表明化合物1的酒石酸盐和磷酸西格列汀通过对肝细胞的直接作用抑制脂肪蓄积,同时结合由内源性GLP-1水平增加引起的间接作用,能够表现出预防脂肪肝的作用。
实施例6:化合物1的酒石酸盐、磷酸西格列汀和维格列汀对CCl
4
-
诱导的急性肝损伤小鼠动物模型中的TGF-β1的活化的抑制作用
为了研究本发明的化合物对CCl4-诱导的急性肝损伤小鼠模型中的TGF-β1(已知其在肝细胞的纤维化过程中具有重要作用)的表达的抑制作用,进行以下实验。使7周龄的雄性C57BL/6小鼠稳定化并根据体重分成9个组(n=7),然后腹膜内给药CCl4(0.1ml/kg)。向正常对照组给予橄榄油。以24小时为间隔,以10ml/kg的剂量向对照组每日一次口服给予媒介物溶液(0.5%MC),持续3天。对应所命名的组,分别向剩余的组每日一次口服给药30、100和300mg/kg剂量的化合物1的酒石酸盐、100和300mg/kg剂量的磷酸西格列汀(根据WO2004/085378或WO2005/003135中记载的方法制备)以及100和300mg/kg剂量的维格列汀(Trademax,中国)。末次口服给药后1小时,将动物解剖并评价切除的肝脏的TGF-β1 mRNA表达。将保存在液氮中的肝组织在TRIZOL溶液中匀浆,然后提取总RNA。在0.1(v/v)%DEPC(焦碳酸二乙酯)中将分离的RNA稀释至1μg/μL的浓度,然后使用PCR仪于72℃将RNA混合物[2μg/μL各RNA+2μL 0.5μg/μLoligo d(T)15+最多15μL 0/1%DEPC水]温育5分钟,然后在冰上终止反应。制备混合物[1μL PCR核苷酸混合物+5μL 5X MMLV RT bf.(Promega,M531A)+1μL 200μg/μL M-MLV逆转录酶],然后使其于42℃延伸60分钟,于95℃变性5分钟并于8℃终止反应来合成cDNA,将其保存于-20℃直到后续使用。为了进行RT-PCR,制备混合物[1μL 20pmol各引物+9.5μL不含核酶的水],然后将2μL各cDNA置于无菌PCR管中,然后向其中加入12.5μL remix TaqTM(RR003A,TaKaRa),然后混匀。使用Thermal Cycler(PTC-200,MJ Research)在以下条件下(表4)进行PCR。将PCT产物电泳并使用Image Analyzer(Vilber Lourmat)分析。用β-肌动蛋白表达将目标基因TGF-β1的表达标准化(图11)。结果显示于表5。
[表4]RT-PCR试验条件和PCR引物序列
[表5]化合物1的酒石酸盐、磷酸西格列汀和维格列汀对CCl4诱导的急性肝损伤小鼠模型中的TGF-β1的活化的抑制作用
*通过将CCl4对照组相对于正常组的增加幅度作为100%而得到的产生增加的抑制%
结果显示于表5和图11,与正常组相比,CCl4对照组表现出肝脏TGF-β1的mRNA表达增加22%,将化合物1的酒石酸盐和维格列汀的TGF-β1的表达标准化。磷酸西格列汀治疗组还表现出与CCl4组相比TGF-β1的表达降低,因此表明对CCl4诱导的TGF-β1表达的抑制作用。另外,相对于CCl4对照组,肝脏TGF-β1 mRNA表达的减量在给药化合物1的酒石酸盐的组中最大值为135%,在给药西格列汀的组中最大值为41%,在给药维格列汀的组中最大值为115%,由此表明本发明的化合物对由TGF-β1表达增加引起的肝纤维化的发生具有治疗功效。
实施例7:化合物1的酒石酸盐和磷酸西格列汀在肥胖症动物模型
ob/ob小鼠中的降低丙氨酸转氨酶的作用
为了研究化合物1的酒石酸盐和磷酸西格列汀对单纯脂肪变性的治疗作用,进行以下实验。
使5周龄的雄性C57BL/6小鼠(正常小鼠组)和ob/ob小鼠(肥胖症小鼠组)稳定化,然后根据体重和血糖水平分成6个组,然后用标准饲料和与混合有药物的饲料饲养。小鼠的饲料消耗量显示为约1g/10g小鼠体重的饲料摄入。因此,为了提供10、100和300mg/kg的化合物1的酒石酸盐的每日目标剂量,通过将标准饲料分别与0.01重量%、0.1重量%和0.3重量%的化合物1的酒石酸盐以及0.3重量%的磷酸西格列汀混合来配制饲料。提供饲料后4周,将动物解剖并分离血清。使用血液分析仪测定血浆丙氨酸转氨酶水平(表6)。
[表6]化合物1的酒石酸盐和磷酸西格列汀在肥胖症动物模型ob/ob小鼠中的降低血浆丙氨酸转氨酶(ALT)的作用
*通过将高脂肪饲料相对于标准饲料的增加幅度作为100%而得到的产生增加的抑制%
结果验证了给药化合物1的酒石酸盐或磷酸西格列汀导致血浆丙氨酸转氨酶减少。这些结果表明,化合物1的酒石酸盐和磷酸西格列汀表现出对脂肪肝引起的丙氨酸转氨酶增加的降低作用并因此可用作治疗单纯脂肪变性的治疗剂。
Claims (27)
2.权利要求1的组合物,其中所述活性成分是式I表示的化合物1或其药学可接受的盐。
3.权利要求2的组合物,其中所述活性成分是化合物1的酒石酸盐。
4.权利要求1的组合物,其中所述活性成分是西格列汀或其药学可接受的盐。
5.权利要求4的组合物,其中所述活性成分是磷酸西格列汀。
6.权利要求1的组合物,其中所述活性成分是维格列汀或其药学可接受的盐。
7.权利要求1的组合物,其中所述活性成分是利拉利汀或其药学可接受的盐。
8.权利要求1-7中任一项的组合物,其中所述非酒精性脂肪性肝病是由高脂血症、糖尿病或肥胖症引起的。
9.权利要求1-7中任一项的组合物,其中所述非酒精性脂肪性肝病选自单纯脂肪变性、非酒精性脂肪性肝炎、肝纤维化和肝硬化。
11.权利要求10的方法,其中所述活性成分是式I表示的化合物1或其药学可接受的盐。
12.权利要求11的方法,其中所述活性成分是化合物1的酒石酸盐。
13.权利要求10的方法,其中所述活性成分是西格列汀或其药学可接受的盐。
14.权利要求13的方法,其中所述活性成分是磷酸西格列汀。
15.权利要求10的方法,其中所述活性成分是维格列汀或其药学可接受的盐。
16.权利要求10的方法,其中所述活性成分是利拉利汀或其药学可接受的盐。
17.权利要求10-16中任一项的方法,其中所述非酒精性脂肪性肝病是由高脂血症、糖尿病或肥胖症引起的。
18.权利要求10-16中任一项的方法,其中所述非酒精性脂肪性肝病选自单纯脂肪变性、非酒精性脂肪性肝炎、肝纤维化和肝硬化。
20.权利要求19的用途,其中所述活性成分是式I表示的化合物1或其药学可接受的盐。
21.权利要求20的用途,其中所述活性成分是化合物1的酒石酸盐。
22.权利要求19的用途,其中所述活性成分是西格列汀或其药学可接受的盐。
23.权利要求22的用途,其中所述活性成分是磷酸西格列汀。
24.权利要求19的用途,其中所述活性成分是维格列汀或其药学可接受的盐。
25.权利要求19的用途,其中所述活性成分是利拉利汀或其药学可接受的盐。
26.权利要求19-25中任一项的用途,其中所述非酒精性脂肪性肝病是由高脂血症、糖尿病或肥胖症引起的。
27.权利要求19-25中任一项的用途,其中所述非酒精性脂肪性肝病选自单纯脂肪变性、非酒精性脂肪性肝炎、肝纤维化和肝硬化。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2010-0026134 | 2010-03-24 | ||
KR20100026134 | 2010-03-24 | ||
PCT/KR2011/001988 WO2011118976A2 (en) | 2010-03-24 | 2011-03-23 | Pharmaceutical composition for the prevention or the treatment of non-alcoholic fatty liver disease and the method for prevention or treatment of non-alcoholic fatty liver disease using the same |
Publications (1)
Publication Number | Publication Date |
---|---|
CN102883721A true CN102883721A (zh) | 2013-01-16 |
Family
ID=44673755
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2011800153529A Pending CN102883721A (zh) | 2010-03-24 | 2011-03-23 | 用于预防或治疗非酒精性脂肪性肝病的药物组合物以及使用所述药物组合物预防或治疗非酒精性脂肪性肝病的方法 |
Country Status (12)
Country | Link |
---|---|
US (1) | US20130072459A1 (zh) |
EP (1) | EP2549997A4 (zh) |
JP (1) | JP2013522359A (zh) |
KR (1) | KR20110107287A (zh) |
CN (1) | CN102883721A (zh) |
AU (1) | AU2011230081A1 (zh) |
BR (1) | BR112012023139A2 (zh) |
CA (1) | CA2790914A1 (zh) |
MX (1) | MX2012009855A (zh) |
RU (1) | RU2012145116A (zh) |
SG (1) | SG183817A1 (zh) |
WO (1) | WO2011118976A2 (zh) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104523703A (zh) * | 2014-12-24 | 2015-04-22 | 聂飚 | 一种游离脂肪酸转运蛋白小分子抑制物的应用 |
CN105307652A (zh) * | 2013-07-10 | 2016-02-03 | 兴和株式会社 | 非酒精性脂肪性肝病治疗剂 |
CN109789147A (zh) * | 2016-09-27 | 2019-05-21 | 田边三菱制药株式会社 | 用于治疗非酒精性脂肪性肝病的药物组合物及方法 |
CN110151787A (zh) * | 2018-02-12 | 2019-08-23 | 玛旺干细胞医学生物科技股份有限公司 | 护肝组合物及其用途 |
WO2020063463A1 (zh) * | 2018-09-25 | 2020-04-02 | 深圳微芯生物科技股份有限公司 | 西格列羧及其相关化合物的应用 |
CN112755011A (zh) * | 2020-09-15 | 2021-05-07 | 艾斯生物医药株式会社 | 一种用于预防或治疗肝病的组合物 |
CN115192568A (zh) * | 2014-12-15 | 2022-10-18 | 帝斯曼知识产权资产管理有限公司 | 对非酒精性脂肪肝疾病的新颖治疗 |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101180174B1 (ko) | 2010-04-23 | 2012-09-05 | 동아제약주식회사 | 신규한 벤즈아미드 유도체 |
KR101341693B1 (ko) | 2011-03-16 | 2013-12-16 | 동아에스티 주식회사 | 생약추출물을 함유하는 퇴행성 신경질환의 치료 및 예방을 위한 조성물 |
KR101341692B1 (ko) | 2011-03-16 | 2013-12-20 | 동아에스티 주식회사 | 복합생약추출물을 함유하는 당뇨병성 말초 신경병증의 치료 및 예방을 위한 조성물 |
WO2015111967A1 (ko) * | 2014-01-23 | 2015-07-30 | 동국대학교 산학협력단 | 페녹시아크릴 유도체 및 이의 용도 |
KR101629642B1 (ko) | 2014-06-25 | 2016-06-13 | 서울대학교산학협력단 | 피퍼롱구민을 유효성분으로 함유하는 지방간 예방용 식품 조성물, 지방간 치료용 약학 조성물, 지방간 치료용 동물 의약품 및 사료 조성물 |
US11730742B2 (en) | 2018-03-09 | 2023-08-22 | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | Pharmaceutical use of thiophene [3,2-d] pyrimidine-4-ketone compound |
CN108743914A (zh) * | 2018-07-23 | 2018-11-06 | 江西本草天工科技有限责任公司 | Vvyp肽或其盐在制备预防或治疗非酒精性脂肪性肝病药物中的应用 |
CN108947982A (zh) * | 2018-08-16 | 2018-12-07 | 刘璐 | 治疗非酒精性脂肪肝病的吡嗪衍生物、组合物和应用 |
CA3113579A1 (en) * | 2018-09-12 | 2020-03-19 | Dong-A St Co., Ltd. | Pharmaceutical composition for preventing or treating nonalcoholic fatty liver disease, containing gpr119 ligand as active ingredient |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009147125A1 (en) * | 2008-06-03 | 2009-12-10 | Boehringer Ingelheim International Gmbh | Dpp-iv inhibitors for use in the treatment of nafld |
CN101663282A (zh) * | 2007-04-19 | 2010-03-03 | 东亚制药株式会社 | 包含β-氨基的DPP-Ⅳ抑制剂及其制备方法以及用于预防和治疗糖尿病或肥胖症的含有所述抑制剂的药物组合物 |
-
2011
- 2011-03-23 SG SG2012063301A patent/SG183817A1/en unknown
- 2011-03-23 AU AU2011230081A patent/AU2011230081A1/en not_active Abandoned
- 2011-03-23 US US13/636,670 patent/US20130072459A1/en not_active Abandoned
- 2011-03-23 BR BR112012023139A patent/BR112012023139A2/pt not_active IP Right Cessation
- 2011-03-23 EP EP11759725.2A patent/EP2549997A4/en not_active Withdrawn
- 2011-03-23 JP JP2013501186A patent/JP2013522359A/ja active Pending
- 2011-03-23 RU RU2012145116/15A patent/RU2012145116A/ru not_active Application Discontinuation
- 2011-03-23 MX MX2012009855A patent/MX2012009855A/es not_active Application Discontinuation
- 2011-03-23 CN CN2011800153529A patent/CN102883721A/zh active Pending
- 2011-03-23 CA CA2790914A patent/CA2790914A1/en not_active Abandoned
- 2011-03-23 KR KR1020110025759A patent/KR20110107287A/ko not_active Application Discontinuation
- 2011-03-23 WO PCT/KR2011/001988 patent/WO2011118976A2/en active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101663282A (zh) * | 2007-04-19 | 2010-03-03 | 东亚制药株式会社 | 包含β-氨基的DPP-Ⅳ抑制剂及其制备方法以及用于预防和治疗糖尿病或肥胖症的含有所述抑制剂的药物组合物 |
WO2009147125A1 (en) * | 2008-06-03 | 2009-12-10 | Boehringer Ingelheim International Gmbh | Dpp-iv inhibitors for use in the treatment of nafld |
Non-Patent Citations (1)
Title |
---|
GIOVANNI MUSSO 等: "Emerging Molecular Targets for the Treatment of Nonalcoholic Fatty Liver Disease", 《ANNU. REV. MED.》 * |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105307652A (zh) * | 2013-07-10 | 2016-02-03 | 兴和株式会社 | 非酒精性脂肪性肝病治疗剂 |
CN115192568A (zh) * | 2014-12-15 | 2022-10-18 | 帝斯曼知识产权资产管理有限公司 | 对非酒精性脂肪肝疾病的新颖治疗 |
CN104523703A (zh) * | 2014-12-24 | 2015-04-22 | 聂飚 | 一种游离脂肪酸转运蛋白小分子抑制物的应用 |
CN109789147A (zh) * | 2016-09-27 | 2019-05-21 | 田边三菱制药株式会社 | 用于治疗非酒精性脂肪性肝病的药物组合物及方法 |
CN110151787A (zh) * | 2018-02-12 | 2019-08-23 | 玛旺干细胞医学生物科技股份有限公司 | 护肝组合物及其用途 |
WO2020063463A1 (zh) * | 2018-09-25 | 2020-04-02 | 深圳微芯生物科技股份有限公司 | 西格列羧及其相关化合物的应用 |
RU2769446C1 (ru) * | 2018-09-25 | 2022-03-31 | Шэньчжэнь Чипскрин Байосайенсиз Ко., Лтд. | Применение чиглитазара и родственных ему соединений |
CN112755011A (zh) * | 2020-09-15 | 2021-05-07 | 艾斯生物医药株式会社 | 一种用于预防或治疗肝病的组合物 |
Also Published As
Publication number | Publication date |
---|---|
US20130072459A1 (en) | 2013-03-21 |
EP2549997A4 (en) | 2014-05-14 |
WO2011118976A3 (en) | 2012-03-15 |
CA2790914A1 (en) | 2011-09-29 |
WO2011118976A2 (en) | 2011-09-29 |
AU2011230081A1 (en) | 2012-09-20 |
SG183817A1 (en) | 2012-10-30 |
KR20110107287A (ko) | 2011-09-30 |
JP2013522359A (ja) | 2013-06-13 |
EP2549997A2 (en) | 2013-01-30 |
MX2012009855A (es) | 2012-09-21 |
RU2012145116A (ru) | 2014-04-27 |
BR112012023139A2 (pt) | 2018-06-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102883721A (zh) | 用于预防或治疗非酒精性脂肪性肝病的药物组合物以及使用所述药物组合物预防或治疗非酒精性脂肪性肝病的方法 | |
EP3613759A1 (en) | Peptide having anti-diabetic and anti-obesity effects, and use thereof | |
EP3498279A1 (en) | Pharmaceutical composition comprising amodiaquine and anti-diabetes drug as effective ingredient for prevention or treatment of diabetes | |
CN103037692A (zh) | 用于抑制肌萎缩的方法 | |
JP6853783B2 (ja) | シリビンを含有する薬物組成物 | |
CN114790160B (zh) | 一种茴香霉素衍生物以及茴香霉素和其衍生物作为glp-1r激动剂的用途 | |
US10959963B2 (en) | Method for the treatment of fatty liver disease | |
US11920157B2 (en) | Applications of butylidenephthalide | |
WO2017133057A1 (zh) | 五味子木脂素类化合物的医药用途 | |
CN118178446A (zh) | 三乙酰基-3-羟基苯基腺苷在制备预防或者治疗非酒精性脂肪肝药物中的应用 | |
EP3967302A1 (en) | Composition for preventing or treating liver diseases | |
CN111067900A (zh) | 治疗或预防肥胖或其相关疾病的化合物及其应用 | |
CN106727469A (zh) | 地骨皮乙素在制备治疗ⅱ型糖尿病药物中的应用 | |
CN110946986B (zh) | 一种寡肽在制备防治非酒精性脂肪肝病药物中的应用 | |
CN113209099A (zh) | 木兰花碱在制备调节食欲亢进或治疗肥胖症的药物中的应用 | |
Khadka et al. | The study of drug induced hepatotoxicity in ATT patients attending in national tuberculosis center in Bhaktapur | |
CN115607546A (zh) | Isarubrolone C、包含Isarubrolone C的药物组合物及应用 | |
KR101613252B1 (ko) | 아르기나아제 억제제를 함유하는 비만 및 지방간 예방 또는 치료용 조성물 | |
ES2730943T3 (es) | Fármaco para tratar lesiones hepáticas causadas por la acción de agentes químicos o biológicos | |
WO2024060359A1 (zh) | 甘油磷脂类化合物在预防和治疗高血脂、动脉粥样硬化、非酒精性脂肪肝和肥胖中的用途 | |
CN108283634A (zh) | 白杨素及其衍生物在制备预防和治疗脂肪肝药物中的用途 | |
Haidara et al. | The impact of vanadium on endothelial dysfunction in type 2 diabetic rats: Histological insight | |
TW201038273A (en) | Synthesis and pharmacokinetic activities of pulmodil and pulmodil-1, two chlorophenylpiperazine salt derivatives | |
OA18548A (en) | Peptide having anti-diabetic and anti-obesity effects and use thereof. | |
CN115252630A (zh) | 黄柏酮在制备预防、改善或治疗非酒精性脂肪肝的药物中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1176001 Country of ref document: HK |
|
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20130116 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1176001 Country of ref document: HK |